Updates are available Correction dated 2025-04-25
Click to view Correction: https://doi.org/10.1038/s41591-025-03717-4
-
Authors
Dulery, Remy https://orcid.org/0000-0002-5024-1713
Guiraud, Vincent https://orcid.org/0000-0002-4301-3771
Choquet, Sylvain https://orcid.org/0000-0002-7791-0470
Thieblemont, Catherine https://orcid.org/0000-0002-9941-2448
Bachy, Emmanuel https://orcid.org/0000-0003-2694-7510
Barete, Stéphane https://orcid.org/0000-0003-1593-9750
Todesco, Ève https://orcid.org/0000-0002-9260-8616
Arnulf, Bertrand
Boissel, Nicolas https://orcid.org/0000-0003-2091-7927
Baruchel, André
Bay, Jacques-Olivier https://orcid.org/0000-0002-7032-5180
Le Gouill, Steven
Houot, Roch https://orcid.org/0000-0003-1729-8213
- License Information
-
More Information
Article History
Received: 11 July 2024
Accepted: 11 December 2024
First Online: 8 January 2025
Change Date: 25 April 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41591-025-03717-4
Competing interests
: R.D. reports research funding from Ligue Contre le Cancer, Arthur Sachs Scholarship Fund, Monahan Foundation, Servier Foundation, Philippe Foundation and DCP AP-HP; honoraria from Novartis and Takeda; and support for attending meetings and/or travel from Sanofi and Kite Pharma/Gilead. S.C. reports personal fees from Kite Pharma/Gilead, Novartis, Janssen, Celgene-BMS, Takeda, Atara, Astra Zeneca, Pierre Fabre, Viatris and Lilly. C.T. reports membership on an entity’s Board of Directors or advisory committees of Kite Pharma/Gilead, Amgen, AbbVie, Novartis, Roche, Gilead Sciences, Takeda, BMS/Celgene, Incyte and Cellectis; consultancy for Kite Pharma/Gilead, Amgen, AbbVie, Novartis, Gilead Sciences, Cellectis, Roche and BMS/Celgene; honoraria from Takeda, Incyte, Bayer, Kite Pharma/Gilead, Novartis, BMS, Abbvie, F. Hoffmann-La Roche Ltd., Amgen, Cellectis and Janssen; research funding from Hospira and BMS/Celgene; and support for attending meetings and/or travel from Kite Pharma/Gilead, Amgen, AbbVie, Novartis, Gilead Sciences, Cellectis, Roche, BMS/Celgene and Janssen. E.B. reports participation on a data safety monitoring board or advisory board of Novartis, Kite Pharma/Gilead, Roch, Incyte, ADC Therapeutics, Abbvie and Beigene; consultancy for Kite Pharma/Gilead, Amgen, AbbVie, Novartis, Gilead Sciences, Cellectis, Roche and BMS/Celgene; honoraria from Novartis, Kite Pharma/Gilead, Roche, Takeda, Janssen, Abbvie and Astra Zeneca; research funding from Amgen and BMS; and support for attending meetings and/or travel from Roche, Kite Pharma/Gilead and Novartis. R.H. reports honoraria from Kite Pharma/Gilead, Novartis, Incyte, Janssen, MSD, Takeda, Amgen, Abbvie and Roche; and membership on an entity’s Board of Directors or advisory committees of Kite Pharma/Gilead, Novartis, Bristol-Myers Squibb/Celgene, Incyte, Roche and Miltenyi. The other authors declare no competing interests.
